The androgen receptor (AR) fuels PCa growth [1,2,3]; thus, PCa patients are treated with androgen deprivation therapy (ADT) and, upon recurrence, treated with anti-androgens to block AR activity [2,4,5,6]. The gene discussed is AR; the disease is posterior cortical atrophy.